Clinical Practice Recommendations for the Treatment of Candida auris Infection in Korea.
10 affiliations
- 1Division of Healthcare Associated Infection Control, Korea Disease Control and Prevention Agency, Cheongju, Korea.
- 2Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 3Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
- 4Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 5Department of Laboratory Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
- 6Department of Healthcare Safety and Immunization, Korea Disease Control and Prevention Agency, Cheongju, Korea.
- 7Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 8Department of Pediatrics, Gangnam Severance Hospital, Seoul, Korea.
- 9Pyeongtaek Samsung Convalescent Hospital, Pyeongtaek, Korea.
- 10Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. [email protected].
Abstract
Candida auris is an emerging multidrug-resistant fungal pathogen associated with invasive infections and high mortality. In Korea, C. auris infections have historically been caused predominantly by Clade II isolates; however, recent reports of invasive infections due to Clade I indicate an evolving epidemiology with potential implications for antifungal resistance and treatment strategies. To provide practical guidance for clinicians, we developed evidence-based recommendations for the management of C. auris infections in Korea through review of current international guidelines and available epidemiologic and clinical data, with multidisciplinary expert consensus. Antifungal therapy is not recommended for asymptomatic colonization. Echinocandins are recommended as first-line therapy for suspected or confirmed invasive C. auris infection, whereas amphotericin B deoxycholate is preferred for neonates and young infants. Antifungal susceptibility testing should be performed whenever invasive infection is suspected, although initiation of empirical therapy should not be delayed while awaiting results. Treatment should be reassessed according to susceptibility results, infection sites, and clinical response, with specialist consultation for refractory or complicated infections. These recommendations are based on the currently available evidence and epidemiology, warranting continued surveillance of epidemiologic changes and emerging clinical data.
Related
- Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice
- Towards global clinical practice guidelines for the management of non-specific low back pain in primary care: a review of current guideline recommendations and how they have changed over the last 30 years
- Challenges and recommendations for implementation of oncology clinical practice guidelines in China
- Addressing heterogeneity in trauma responses in research and clinical practice: reflections and recommendations from early career researchers.
- AO Spine Clinical Practice Recommendations for Interbody Fusion at the Lumbo-Sacral Junction.
BibTeX
@article{lee2026clinical,
title = {{Clinical Practice Recommendations for the Treatment of Candida auris Infection in Korea.}},
author = {Su-Yeon Lee and Jae-Hoon Ko and Nam Yi Kim and Tae Hyong Kim and Jae Woo Park and In Young Yoo and Mi-Kyung Lee and Seung Gul Lee and Tong Ryoung Jung and Yong Pil Chong and Joon-Sik Choi and Chang Young Ha and Dong-Gun Lee},
journal = {Infection \& chemotherapy},
year = {2026},
month = sep,
doi = {10.3947/ic.2026.0109},
url = {https://europepmc.org/article/MED/42847626},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Clinical Practice Recommendations for the Treatment of Candida auris Infection in Korea.
AU - Su-Yeon Lee
AU - Jae-Hoon Ko
AU - Nam Yi Kim
AU - Tae Hyong Kim
AU - Jae Woo Park
AU - In Young Yoo
AU - Mi-Kyung Lee
AU - Seung Gul Lee
AU - Tong Ryoung Jung
AU - Yong Pil Chong
AU - Joon-Sik Choi
AU - Chang Young Ha
AU - Dong-Gun Lee
PY - 2026
DA - 2026/09/01
JO - Infection & chemotherapy
DO - 10.3947/ic.2026.0109
UR - https://europepmc.org/article/MED/42847626
AB - Candida auris is an emerging multidrug-resistant fungal pathogen associated with invasive infections and high mortality. In Korea, C. auris infections have historically been caused predominantly by Clade II isolates; however, recent reports of invasive infections due to Clade I indicate an evolving epidemiology with potential implications for antifungal resistance and treatment strategies. To provide practical guidance for clinicians, we developed evidence-based recommendations for the management of C. auris infections in Korea through review of current international guidelines and available epidemiologic and clinical data, with multidisciplinary expert consensus. Antifungal therapy is not recommended for asymptomatic colonization. Echinocandins are recommended as first-line therapy for suspected or confirmed invasive C. auris infection, whereas amphotericin B deoxycholate is preferred for neonates and young infants. Antifungal susceptibility testing should be performed whenever invasive infection is suspected, although initiation of empirical therapy should not be delayed while awaiting results. Treatment should be reassessed according to susceptibility results, infection sites, and clinical response, with specialist consultation for refractory or complicated infections. These recommendations are based on the currently available evidence and epidemiology, warranting continued surveillance of epidemiologic changes and emerging clinical data.
SN - 2093-2340
SN - 2092-6448
ER -